慢性乙型肝炎免疫清除期甲胎蛋白与HBV DNA清除的相关性研究被引量：4

Correlation between serum alpha-fetoprotein level and HBV DNA clearance in immune clearance phase of patients with chronic hepatitis B

原文传递

导出

摘要目的探讨乙型肝炎免疫清除期,甲胎蛋白(AFP)与HBV DNA清除之间的相关性。方法收集处于免疫清除期发病2周内AFP升高5倍以上患者共58例,分为非抗病毒治疗组(下称观察组)31例和核苷(酸)类似物抗病毒治疗组(下称阳性对照组)27例,另取同期住院AFP阴性首次发病的慢性乙型肝炎核苷(酸)类似物抗病毒患者30例作为阴性对照组。分析影响HBV DNA清除率的相关因素。结果阳性对照组及阴性对照组患者均行抗病毒治疗,HBV DNA定量与各临床数据之间均无相关性,观察组HBV DNA定量与各指标之间的关系结果显示,AFP与HBV DNA清除具有显著相关性(r=0.8420,P=0.018),以下依次为ALT(r=0.7888,P=0.027)和总胆红素(TBil)(r=0.7816,P=0.032)。HBsAg(r=0.0480,P=0.413)和HBeAg(r=0.3356,P=0.191)与HBV DNA清除无显著相关性。结论对乙型肝炎免疫清除期AFP升高5倍以上患者,可先进行密切病情观察,根据病情需要进行抗病毒治疗。 Objectives To investigate the relationship between serum alpha-fetoprotein level and HBV DNA clearance in immune clearance phase of patients with chronic hepatitis B （CHB）. Methods Total of 58 cases with CHB, who were in immune clearance phase and the serum alpha-fetoprotein level〉5 upper limits of normal in two weeks since disease onset were enrolled. Among which 31 cases received non-antiviral therapy as experimental group, and 27 cases received antiviral therapy as positive control group. While other 30 cases with CHB who were in immune clearance phase and the serum alpha-fetoprotein level were normal in two weeks since disease onset, were enrolled as negative control group. And the correlation factors of HBV DNA clearance were analyzed, respectively. Results There were no signiifcant correlation between HBV DNA clearance and other data in patients who received antiviral therapy in positive and negative control group. In experimental group, there were positive correlation between HBV DNA clearance and serum alpha-fetoprotein level （r=0.8420, P=0.018）, and inturn were alanine aminotransferase （r=0.7888, P=0.027）, total bilirubin （TBil）（r=0.7816, P=0.032）, but there were no signiifcant correlation among HBV DNA clearance with HBsAg （r=0.0480, P=0.413） and HBeAg （r=0.3356, P=0.191）. Conclusions Patients with CHB who were in immune clearance phase and the serum alpha-fetoprotein level 〉5 upper limits of normal, might be close surveyed ifrstly, and might be given antiviral therapy when need.

作者庞晓鹰徐洪涛杨秀珍咸建春沈美龙

机构地区江苏省泰州市人民医院肝科

出处《中华实验和临床感染病杂志（电子版）》 CAS 2014年第2期65-68,共4页 Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)

关键词肝炎乙型慢性免疫清除期甲胎蛋白 HBV DNA Chronic hepatitis B Immune clearance phase Alpha-fetoprotein HBV DNA

分类号 R512.62 [医药卫生—内科学]

引文网络
相关文献

参考文献14

1Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and fututre challenges[J]. QJM,2012,105(2): 109-113.
2European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol,2012,57(1): 167-185.
3Nakao K, Ichikawa T. Recent topics on alpha-fetoprotein[J]. Hepatol Res,2013,43(8):820-825.
4中华医学会肝病学分会,中华医学会感染病学分会.慢性己型肝炎防治指南(2010年版)[J].中国病毒病杂志,2011,1(3):9-23.
5Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed?[J]. Liver Int,2012,32(9): 1333-1341.
6Szpakowski JL, Tucker LY. Causes of death in patients with hepatitis B: a natural history cohort study in the United States[J]. Hepatology,2013,58(1):21-30.
7Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools[J]. Biologics,2012,6(1):207-219.
8Mondal G, Chatterjee U, Chawla YK, et al. Alterations of glycan branching and differential expression of sialic acid on alpha fetoprotein among hepatitis patients[J]. Glycoconj J,2011,28( 1): 1-9.
9Bae JS, Park S J, Park KB, et al. Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma[J]. Korean J Intern Med,2005,20 (1):80-85.
10Tai WC, Hu TH, Wang JH, et al. Clinical implications of alpha-fetoprotein in chronic hepatitis C[J]. J Formos Med Assoc,2009,108(3) :210-218.